If enacted, SB3794 is expected to enhance the oversight of large-scale outsourcing facilities by mandating more rigorous inspections. Facilities compounding over 100 products annually will be subjected to pre-compounding inspections and biennial reinspections. This will help to identify and mitigate potential risks in the production of compounded medications, thereby improving patient safety. Additionally, the bill seeks to enforce reporting requirements for pharmacies compounding for out-of-state patients, requiring them to submit detailed reports to the Secretary of Health annually. The intent is to ensure greater accountability and monitor the distribution of compounded drugs, ultimately tightening the regulatory framework surrounding compounded medications.
Summary
SB3794, also known as the 'SAFE Drugs Act of 2026', aims to amend the Federal Food, Drug, and Cosmetic Act to implement stricter regulations on compounding pharmacies and outsourcing facilities. The bill introduces definitions regarding the compounding of drug products, specifically targeting the number of times a drug product can be compounded based on its similarity to commercially available drugs. The key provision specifies that compounding pharmacies may not create a product that is essentially a copy of a commercially available drug more than 20 times in a single month, ensuring regulations prioritize safety and effectiveness for patients who require individualized medications.
Contention
Discussions surrounding SB3794 may center around the balance of regulatory oversight and the operational flexibility of compounding pharmacies. Supporters argue that these regulations are necessary to prevent unsafe practices and protect patients from potentially harmful compounded medications. Critics, however, may raise concerns about the burden placed on smaller pharmacies, potentially limiting their ability to serve patients with specific needs, especially if compliance costs increase. Overall, the bill reflects an ongoing debate about the extent to which the federal government should regulate local healthcare practices and the implications this has for patient care and pharmacy operations.
Patient Access to Urgent-Use Pharmacy Compounding Act of 2023 This bill relaxes certain requirements for compounding drugs that are facing shortages. Drug compounding is the process of mixing or otherwise altering drugs to create a medication. Currently, the Food and Drug Administration (FDA) allows for drug compounding subject to certain requirements. Generally, a licensed pharmacist or physician not registered with the FDA may only compound drugs in limited quantities for prescriptions for a specific individual patient. On the other hand, an FDA-registered outsourcing facility may compound drugs in bulk for use in medical facilities but is subject to additional requirements. This bill allows a compounder not registered with the FDA to compound drugs in limited quantities for an urgent medical need not involving a specific patient if, among other requirements (1) the prescriber certifies that the prescriber is unable, despite reasonable attempts, to obtain certain related drugs with the same active ingredient and route of administration; (2) the compounded drug meets certain labeling requirements, including an indication that the compounded drug is provided only for urgent administration to a patient; and (3) the compounder requests and maintains certain records about patients receiving the compounded drug. Furthermore, a restriction against an unregistered compounder regularly compounding (or compounding inordinate amounts of) what is essentially a copy of a commercially available drug shall not apply if the drug is on a shortage list maintained by the FDA or the American Society of Hospital Pharmacists.